Printed from Voxsanity (voxsanity.com.au) — NCT07277231 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.
AI generated eligibility summary.
Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source.
How we use AI
Who might be able to join this trial:
Adults who have been diagnosed with a type of blood cancer called CLL (chronic lymphocytic leukemia) that needs treatment, and who have not yet received any treatment for it
People whose general health and ability to carry out daily activities falls within an acceptable range, as measured by a standard medical scoring system (called the ECOG scale, scored 0, 1, or 2)
People whose cancer can be detected and measured on a CT or MRI scan
People whose bone marrow and major organs (such as kidneys and liver) are functioning adequately
Who may not be able to join:
People who have previously received systemic (whole-body) treatment for CLL
People who have a related blood condition called prolymphocytic leukemia, or who have had, or are suspected of having, a serious transformation of their CLL called Richter's transformation
People whose CLL has spread to the central nervous system (brain and spinal cord)
People who have had a serious brain condition called progressive multifocal leukoencephalopathy (PML)
People with high blood pressure that is not well controlled, or with significant heart or blood vessel disease
Important: Always verify eligibility with the trial site directly before applying.
Note: Additional eligibility criteria not listed here may also apply, as defined in the trial protocol.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.
Contact this trial
Principal Investigator: Study Director, BeOne Medicines
Blacktown Cancer and Haematology Centre, Blacktown, New South Wales
Concord Repatriation General Hospital, Concord, New South Wales
Genesiscare North Shore, St Leonards, New South Wales
Princess Alexandra Hospital, Woolloongabba, Queensland
Monash Health, Clayton, Victoria
Austin Health, Heidelberg, Victoria
Cabrini Hospital Malvern, Malvern, Victoria
The Alfred Hospital, Melbourne, Victoria
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Voxsanity
Clinical trials and treatments, explained plainly · voxsanity.com.au
Date:
To: My Doctor
Re: Clinical trial enquiry
I am writing to enquire about the following clinical trial which may be relevant to my care:
Trial: NCT07277231
Sponsor: BeOne Medicines
Phase: Phase 3
Status: Recruiting
Condition: Leukaemia
Trial contact: 8778285568
More information: https://clinicaltrials.gov/study/NCT07277231
Eligibility summary (AI generated)
Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.
Who might be able to join this trial:
Adults who have been diagnosed with a type of blood cancer called CLL (chronic lymphocytic leukemia) that needs treatment, and who have not yet received any treatment for it
People whose general health and ability to carry out daily activities falls within an acceptable range, as measured by a standard medical scoring system (called the ECOG scale, scored 0, 1, or 2)
People whose cancer can be detected and measured on a CT or MRI scan
People whose bone marrow and major organs (such as kidneys and liver) are functioning adequately
Who may not be able to join:
People who have previously received systemic (whole-body) treatment for CLL
People who have a related blood condition called prolymphocytic leukemia, or who have had, or are suspected of having, a serious transformation of their CLL called Richter's transformation
People whose CLL has spread to the central nervous system (brain and spinal cord)
People who have had a serious brain condition called progressive multifocal leukoencephalopathy (PML)
People with high blood pressure that is not well controlled, or with significant heart or blood vessel disease
Important: Always verify eligibility with the trial site directly before applying.
Note: Additional eligibility criteria not listed here may also apply, as defined in the trial protocol.
Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.
This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 28 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.
Trial details
Status
Recruiting
Phase
Phase 3
Sponsor
BeOne Medicines
Registry
ClinicalTrials.gov
Start date
22 January 2026
Est. completion
1 February 2031
Where this trial is recruiting
🇦🇺 Australia
🇧🇷 Brazil
🇨🇦 Canada
🇨🇳 China
🇨🇿 Czechia
🇫🇷 France
🇩🇪 Germany
🇮🇹 Italy
🇳🇱 Netherlands
🇳🇿 New Zealand
🇵🇱 Poland
🇷🇴 Romania
🇰🇷 South Korea
🇪🇸 Spain
🇸🇪 Sweden
🇬🇧 United Kingdom
🇺🇸 United States
8 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Progression-Free Survival (PFS) as Determined by Independent Review Committee (IRC); Rate of Undetectable Minimal Residual Disease at < 10^-4 sensitivity (uMRD4)
Can't join this trial?
Expanded access pathways
If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.
Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.